JP2014512375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512375A5 JP2014512375A5 JP2014505642A JP2014505642A JP2014512375A5 JP 2014512375 A5 JP2014512375 A5 JP 2014512375A5 JP 2014505642 A JP2014505642 A JP 2014505642A JP 2014505642 A JP2014505642 A JP 2014505642A JP 2014512375 A5 JP2014512375 A5 JP 2014512375A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- binding site
- group
- formula
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(C1C(C)C1)C(N(*)C(C)N(C)C(*)=O)=O Chemical compound CCC(C1C(C)C1)C(N(*)C(C)N(C)C(*)=O)=O 0.000 description 32
- PJMAADUWXUTYNS-UHFFFAOYSA-N CN1OCCCC1 Chemical compound CN1OCCCC1 PJMAADUWXUTYNS-UHFFFAOYSA-N 0.000 description 2
- LDNJBFXBPNTBSF-UHFFFAOYSA-N C=[I]N1OCCCC1 Chemical compound C=[I]N1OCCCC1 LDNJBFXBPNTBSF-UHFFFAOYSA-N 0.000 description 1
- FZXMCGVUZCPHLC-UHFFFAOYSA-N CC(C1)NCC1OC(NN)=O Chemical compound CC(C1)NCC1OC(NN)=O FZXMCGVUZCPHLC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163467.1 | 2011-04-21 | ||
| EP11163470 | 2011-04-21 | ||
| EP11163470.5 | 2011-04-21 | ||
| EP11163467 | 2011-04-21 | ||
| EP11163474.7 | 2011-04-21 | ||
| EP11163472.1 | 2011-04-21 | ||
| EP11163472 | 2011-04-21 | ||
| EP11163474 | 2011-04-21 | ||
| EP11168556.6 | 2011-06-01 | ||
| EP11168558.2 | 2011-06-01 | ||
| EP11168559.0 | 2011-06-01 | ||
| EP11168558 | 2011-06-01 | ||
| EP11168557.4 | 2011-06-01 | ||
| EP11168557 | 2011-06-01 | ||
| EP11168559 | 2011-06-01 | ||
| EP11168556 | 2011-06-01 | ||
| EP11193623.3 | 2011-12-14 | ||
| EP11193618 | 2011-12-14 | ||
| EP11193609.2 | 2011-12-14 | ||
| EP11193618.3 | 2011-12-14 | ||
| EP11193623 | 2011-12-14 | ||
| EP11193621 | 2011-12-14 | ||
| EP11193621.7 | 2011-12-14 | ||
| EP11193609 | 2011-12-14 | ||
| PCT/EP2012/057247 WO2012143497A2 (de) | 2011-04-21 | 2012-04-20 | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016109316A Division JP6250735B2 (ja) | 2011-04-21 | 2016-05-31 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512375A JP2014512375A (ja) | 2014-05-22 |
| JP2014512375A5 true JP2014512375A5 (enExample) | 2015-09-24 |
| JP6088488B2 JP6088488B2 (ja) | 2017-03-01 |
Family
ID=45976407
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505642A Expired - Fee Related JP6088488B2 (ja) | 2011-04-21 | 2012-04-20 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| JP2014505641A Withdrawn JP2014515753A (ja) | 2011-04-21 | 2012-04-20 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| JP2016109316A Expired - Fee Related JP6250735B2 (ja) | 2011-04-21 | 2016-05-31 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505641A Withdrawn JP2014515753A (ja) | 2011-04-21 | 2012-04-20 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| JP2016109316A Expired - Fee Related JP6250735B2 (ja) | 2011-04-21 | 2016-05-31 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US20130122024A1 (enExample) |
| EP (2) | EP2699268A2 (enExample) |
| JP (3) | JP6088488B2 (enExample) |
| KR (2) | KR20140122649A (enExample) |
| CN (3) | CN103764170A (enExample) |
| AR (2) | AR086363A1 (enExample) |
| AU (3) | AU2012244673A1 (enExample) |
| BR (1) | BR112013027119A8 (enExample) |
| CA (3) | CA2833690A1 (enExample) |
| IL (2) | IL228841A (enExample) |
| MX (1) | MX2013012253A (enExample) |
| RU (2) | RU2610336C2 (enExample) |
| SG (2) | SG194567A1 (enExample) |
| TW (2) | TWI582112B (enExample) |
| WO (4) | WO2012143499A2 (enExample) |
| ZA (1) | ZA201307955B (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| AU2010329904B2 (en) * | 2009-12-09 | 2015-07-09 | Bayer Pharma Aktiengesellschaft | Anti-C4.4a antibodies and uses thereof |
| WO2011154359A1 (de) * | 2010-06-10 | 2011-12-15 | Bayer Pharma Aktiengesellschaft | Neue auristatin-derivate und ihre verwendung |
| JP5933562B2 (ja) | 2010-09-29 | 2016-06-15 | シアトル ジェネティックス， インコーポレイテッド | Ｎ−カルボキシアルキル−アウリスタチンおよびその使用 |
| US9029406B2 (en) | 2011-03-16 | 2015-05-12 | Seattle Genetics, Inc | N-carboxyalkylauristatins and use thereof |
| BR112013027119A8 (pt) * | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | novos conjugados ligante-droga (adcs) e uso dos mesmos |
| SG11201403085PA (en) * | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| EP2927227A4 (en) * | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
| HK1220626A1 (zh) | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| KR20160018579A (ko) * | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| WO2015059147A1 (en) * | 2013-10-25 | 2015-04-30 | Bayer Pharma Aktiengesellschaft | A novel stable formulation |
| JP6671292B2 (ja) * | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| JP6636925B2 (ja) | 2013-12-17 | 2020-01-29 | ノバルティス アーゲー | 細胞障害性ペプチドおよびその抱合体 |
| RU2698697C2 (ru) | 2013-12-23 | 2019-08-29 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего (ADC) с ингибиторами KSP |
| WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| US9260478B2 (en) | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
| WO2015183978A1 (en) * | 2014-05-28 | 2015-12-03 | Agensys, Inc. | Derivatives of dolaproine-dolaisoleuine peptides |
| CA2951368A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| ES2905569T3 (es) | 2014-09-17 | 2022-04-11 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos y métodos para utilizarlos |
| CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| WO2016127790A1 (zh) * | 2015-02-15 | 2016-08-18 | 江苏恒瑞医药股份有限公司 | 配体-细胞毒性药物偶联物、其制备方法及其应用 |
| PT3271329T (pt) | 2015-03-19 | 2021-10-25 | Hangzhou Dac Biotech Co Ltd | Novos ligantes hidrofílicos e conjugados ligando-fármaco dos mesmos |
| AU2016249839B2 (en) | 2015-04-17 | 2021-09-09 | Ventana Medical Systems, Inc. | Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| WO2015151079A2 (en) * | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| US10435435B2 (en) * | 2015-07-24 | 2019-10-08 | The Arizona Board Of Regents On Behalf Of Arizona State University | Quinstatin compounds |
| WO2017058808A1 (en) | 2015-10-02 | 2017-04-06 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| CA3015098A1 (en) | 2016-02-26 | 2017-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | New toxin and method for preparing intermediate thereof |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| WO2018006785A1 (zh) * | 2016-07-05 | 2018-01-11 | 江苏恒瑞医药股份有限公司 | Egfr抗体-药物偶联物及其在医药上的应用 |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| TWI753037B (zh) | 2016-10-26 | 2022-01-21 | 美商星座製藥公司 | Lsd1抑制劑及其用途 |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| CN110312534B (zh) | 2016-12-21 | 2023-04-04 | 拜耳制药股份公司 | 具有酶促可裂解基团的抗体-药物-缀合物(adc) |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| KR20210122319A (ko) * | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| JP7298926B2 (ja) * | 2017-07-12 | 2023-06-27 | ノイスコム アーゲー | 癌の治療のためのネオアンチゲンワクチン組成物 |
| US10646585B2 (en) | 2017-09-15 | 2020-05-12 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and ligand-drug conjugates thereof |
| CN107998453B (zh) * | 2017-12-12 | 2020-09-25 | 中山大学附属第一医院 | 一种表面改性的脱细胞基质及其改性方法 |
| GB201721265D0 (en) * | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| TW202003047A (zh) | 2018-03-23 | 2020-01-16 | 美商西雅圖遺傳學公司 | 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途 |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| EP4054602A4 (en) | 2019-11-08 | 2023-12-06 | Mayo Foundation for Medical Education and Research | EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS |
| EP4087855A1 (en) * | 2020-01-06 | 2022-11-16 | CytomX Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN116669772A (zh) * | 2020-11-19 | 2023-08-29 | 艾迪健公司 | Gpc3结合剂、其缀合物以及使用它们的方法 |
| WO2022105878A1 (en) * | 2020-11-20 | 2022-05-27 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Modified egfr antibody with reduced affinity, drug conjugate, and use thereof |
| WO2022216848A1 (en) * | 2021-04-06 | 2022-10-13 | Hemoshear Therapeutics, Inc. | Methods of treating methylmalonic acidemia and propionic acidemia |
| CN118119409A (zh) | 2021-09-03 | 2024-05-31 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
| CN114149343B (zh) * | 2021-12-06 | 2023-10-20 | 中节能万润股份有限公司 | 一种高纯度1,4-二氰基-2-丁烯的制备方法 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| CA3258612A1 (en) * | 2022-06-09 | 2023-12-14 | Beigene, Ltd. | Antibody drug conjugates |
| TW202412762A (zh) * | 2022-07-27 | 2024-04-01 | 香港商祐方有限公司 | 奧瑞他汀衍生物及其結合物 |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| CN116239513B (zh) * | 2023-05-05 | 2023-08-18 | 天津凯莱英制药有限公司 | Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物 |
| US20260048137A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981003688A1 (en) | 1980-06-13 | 1981-12-24 | Crosby Valve & Eng Co Ltd | Fluid pressure relief system actuator |
| FR2499737B1 (fr) | 1981-02-12 | 1985-07-05 | Laudren Cie Sa Ets M | Circuit d'alarme pour systemes de surveillance de postes telephoniques publics a prepaiement |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| EP0071286B1 (en) | 1981-07-30 | 1985-08-28 | Shell Internationale Researchmaatschappij B.V. | Process for the preparation of carbonate esters |
| DE3223868A1 (de) | 1982-06-25 | 1983-12-29 | Friedrich 8541 Röttenbach Schweinfurter | Turbinenpumpe |
| HUT36107A (en) | 1982-12-04 | 1985-08-28 | Lilly Industries Ltd | Process for production of new aurone-derivatives and medical preparatives consisting of such compounds |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB2163883B (en) | 1984-08-29 | 1989-02-01 | British Aerospace | Data processing arrangement |
| FR2576708B1 (fr) | 1985-01-25 | 1987-04-30 | Novatome | Generateur de vapeur dont le fluide caloporteur est du metal liquide et dont la detection des fuites est effectuee par prelevement de ce metal liquide |
| US4606662A (en) | 1985-01-31 | 1986-08-19 | International Business Machines Corporation | Single stepping motor ribbon and correction feed and lift system |
| US4640839A (en) | 1985-07-01 | 1987-02-03 | Nestec S.A. | Agglomeration process |
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| ES2133139T3 (es) | 1989-10-20 | 1999-09-01 | Medarex Inc | Hetero anticuerpos biespecificos con funciones efectoras dobles. |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2082160C (en) | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| EP0719859B1 (en) | 1994-12-20 | 2003-07-02 | MERCK PATENT GmbH | Anti-alpha V-integrin monoclonal antibody |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| EP0914155B1 (en) | 1996-03-25 | 2006-02-22 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
| WO2000003737A2 (en) * | 1998-07-17 | 2000-01-27 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble drugs and methods for their production |
| CZ20014083A3 (cs) | 1999-05-14 | 2002-08-14 | Imclone Systems Incorporated | Léčivo pro indikaci růstu refrakterních nádorů |
| CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| NZ517331A (en) | 1999-07-29 | 2004-02-27 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| EP1220919A2 (en) | 1999-09-29 | 2002-07-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Metastasis-associated antigen c4.4a |
| ATE419354T1 (de) | 2000-02-25 | 2009-01-15 | Us Gov Health & Human Serv | Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung |
| BR0110927A (pt) | 2000-05-19 | 2003-03-11 | Scancell Ltd | Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| PL207087B1 (pl) | 2001-04-26 | 2010-10-29 | Biogen | Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002311919B8 (en) | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| JP2005520566A (ja) | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ特異的抗体 |
| ES2524767T3 (es) | 2002-06-14 | 2014-12-12 | Immunomedics, Inc. | Anticuerpo monoclonal humanizado HPAM4 |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004091375A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
| KR20130065723A (ko) | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| ATE496944T1 (de) | 2003-07-21 | 2011-02-15 | Immunogen Inc | Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung |
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| EP1701979A2 (en) | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| CA2560305C (en) | 2004-03-19 | 2016-07-05 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| MX2007003907A (es) * | 2004-10-05 | 2007-05-21 | Genentech Inc | Agentes terapeuticos con toxicidad reducida. |
| US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| DE602005022928D1 (de) * | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
| US8603483B2 (en) | 2004-12-09 | 2013-12-10 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods and uses |
| EP2230517A1 (en) | 2005-01-07 | 2010-09-22 | Diadexus, Inc. | OVR110 antibody compositions and methods of use |
| ES2498794T3 (es) | 2005-02-18 | 2014-09-25 | Medarex, L.L.C. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| EP1928912A4 (en) * | 2005-09-07 | 2010-02-24 | Medimmune Inc | EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| EP1957115B8 (en) * | 2005-11-10 | 2014-03-05 | Celldex Therapeutics, Inc. | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| EP2032606B1 (en) * | 2006-05-30 | 2013-11-27 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| EP3539981A1 (en) | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PT2099823E (pt) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| PT2185574E (pt) | 2007-09-07 | 2013-08-26 | Agensys Inc | Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12 |
| US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| ES2526355T3 (es) * | 2007-10-01 | 2015-01-09 | Bristol-Myers Squibb Company | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos |
| MX2010005603A (es) | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
| US9221914B2 (en) | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
| CN101965366B (zh) | 2007-12-26 | 2016-04-27 | 生物测试股份公司 | 靶向cd138的免疫缀合物及其应用 |
| KR101607346B1 (ko) * | 2008-01-31 | 2016-03-29 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| US20110126727A1 (en) | 2008-02-25 | 2011-06-02 | Prittie Allan R | Raised Image Plate Construction with Regions of Varying Support Thickness Beneath the Image Areas |
| EP2260111B2 (en) * | 2008-03-14 | 2022-03-23 | Genentech, Inc. | Genetic variations associated with drug resistance |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
| WO2009140242A1 (en) * | 2008-05-13 | 2009-11-19 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| WO2010022736A2 (en) | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
| CA2754646A1 (en) | 2009-03-31 | 2010-10-07 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
| MX2011013578A (es) | 2009-06-19 | 2012-01-20 | Merck Patent Gmbh | Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer. |
| JP5898082B2 (ja) | 2009-10-07 | 2016-04-06 | マクロジェニクス，インコーポレーテッド | フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法 |
| AU2010329904B2 (en) | 2009-12-09 | 2015-07-09 | Bayer Pharma Aktiengesellschaft | Anti-C4.4a antibodies and uses thereof |
| WO2011154359A1 (de) * | 2010-06-10 | 2011-12-15 | Bayer Pharma Aktiengesellschaft | Neue auristatin-derivate und ihre verwendung |
| JP5933562B2 (ja) * | 2010-09-29 | 2016-06-15 | シアトル ジェネティックス， インコーポレイテッド | Ｎ−カルボキシアルキル−アウリスタチンおよびその使用 |
| BR112013014527A2 (pt) * | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| US9302799B2 (en) * | 2011-02-17 | 2016-04-05 | Sabic Global Technologies B.V. | Method for bulk transporting 2,6-xylenol susceptible to oxidative discoloration |
| US9029406B2 (en) | 2011-03-16 | 2015-05-12 | Seattle Genetics, Inc | N-carboxyalkylauristatins and use thereof |
| BR112013027119A8 (pt) | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | novos conjugados ligante-droga (adcs) e uso dos mesmos |
| SG11201403085PA (en) | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
-
2012
- 2012-04-20 BR BR112013027119A patent/BR112013027119A8/pt not_active IP Right Cessation
- 2012-04-20 SG SG2013078282A patent/SG194567A1/en unknown
- 2012-04-20 CN CN201280028243.5A patent/CN103764170A/zh active Pending
- 2012-04-20 KR KR1020137030468A patent/KR20140122649A/ko not_active Withdrawn
- 2012-04-20 CN CN201280019602.0A patent/CN103826661B/zh not_active Expired - Fee Related
- 2012-04-20 WO PCT/EP2012/057249 patent/WO2012143499A2/de not_active Ceased
- 2012-04-20 CN CN201610450907.7A patent/CN106117312A/zh active Pending
- 2012-04-20 SG SG10201702384PA patent/SG10201702384PA/en unknown
- 2012-04-20 WO PCT/EP2012/057243 patent/WO2012143495A2/de not_active Ceased
- 2012-04-20 KR KR1020137030493A patent/KR102023496B1/ko not_active Expired - Fee Related
- 2012-04-20 WO PCT/EP2012/057245 patent/WO2012143496A2/de not_active Ceased
- 2012-04-20 AU AU2012244673A patent/AU2012244673A1/en not_active Abandoned
- 2012-04-20 RU RU2013151600A patent/RU2610336C2/ru not_active IP Right Cessation
- 2012-04-20 AU AU2012244675A patent/AU2012244675B2/en not_active Ceased
- 2012-04-20 AR ARP120101371A patent/AR086363A1/es unknown
- 2012-04-20 CA CA2833690A patent/CA2833690A1/en not_active Abandoned
- 2012-04-20 US US13/451,916 patent/US20130122024A1/en not_active Abandoned
- 2012-04-20 JP JP2014505642A patent/JP6088488B2/ja not_active Expired - Fee Related
- 2012-04-20 US US13/451,950 patent/US20130066055A1/en not_active Abandoned
- 2012-04-20 TW TW101114203A patent/TWI582112B/zh not_active IP Right Cessation
- 2012-04-20 MX MX2013012253A patent/MX2013012253A/es active IP Right Grant
- 2012-04-20 TW TW106103491A patent/TWI636793B/zh not_active IP Right Cessation
- 2012-04-20 AR ARP120101372A patent/AR086364A1/es unknown
- 2012-04-20 JP JP2014505641A patent/JP2014515753A/ja not_active Withdrawn
- 2012-04-20 RU RU2013151599/04A patent/RU2013151599A/ru not_active Application Discontinuation
- 2012-04-20 EP EP12718624.5A patent/EP2699268A2/de not_active Withdrawn
- 2012-04-20 WO PCT/EP2012/057247 patent/WO2012143497A2/de not_active Ceased
- 2012-04-20 EP EP19150066.9A patent/EP3501546A3/de not_active Withdrawn
- 2012-04-20 CA CA3027793A patent/CA3027793A1/en not_active Abandoned
- 2012-04-20 CA CA2833477A patent/CA2833477A1/en not_active Abandoned
- 2012-04-20 US US14/113,070 patent/US20140127240A1/en not_active Abandoned
- 2012-10-20 US US13/656,681 patent/US8992932B2/en not_active Expired - Fee Related
-
2013
- 2013-10-13 IL IL228841A patent/IL228841A/en active IP Right Grant
- 2013-10-24 ZA ZA2013/07955A patent/ZA201307955B/en unknown
-
2014
- 2014-05-05 US US14/269,577 patent/US20150030618A1/en not_active Abandoned
-
2015
- 2015-05-11 US US14/708,914 patent/US20150246136A1/en not_active Abandoned
-
2016
- 2016-02-24 US US15/052,655 patent/US20160193359A1/en not_active Abandoned
- 2016-05-31 JP JP2016109316A patent/JP6250735B2/ja not_active Expired - Fee Related
- 2016-09-26 IL IL248036A patent/IL248036B/en active IP Right Grant
-
2017
- 2017-06-09 AU AU2017203928A patent/AU2017203928B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512375A5 (enExample) | ||
| JP6088488B2 (ja) | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 | |
| JP2014515753A5 (enExample) | ||
| ES2815098T3 (es) | Conjugados de ligadores (ADCs) con inhibidores de KSP | |
| US20150023989A1 (en) | New antibody drug conjugates (adcs) and the use thereof | |
| CA3012960A1 (en) | Tubulysin analogs and methods for their preparation | |
| NZ625745B2 (en) | FGFR antibody drug conjugates (ADCs) and the use thereof | |
| TW201339175A (zh) | 新黏合劑－藥物接合體（ａｄｃ）及其用途 | |
| NZ615839B2 (en) | Novel binder-drug conjugates (adcs) and their use | |
| HK1231384B (zh) | 含纺锤体驱动蛋白(ksp)的抗体药物偶联物(adc) | |
| TW201302799A (zh) | 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（一） |